Literature DB >> 33536449

Increased random exploration in schizophrenia is associated with inflammation.

Flurin Cathomas1,2, Federica Klaus3,4, Karoline Guetter3, Hui-Kuan Chung5, Anjali Raja Beharelle5,6, Tobias R Spiller7, Rebecca Schlegel3, Erich Seifritz3,6,8, Matthias N Hartmann-Riemer3, Philippe N Tobler5,6,8, Stefan Kaiser9.   

Abstract

One aspect of goal-directed behavior, which is known to be impaired in patients with schizophrenia (SZ), is balancing between exploiting a familiar choice with known reward value and exploring a lesser known, but potentially more rewarding option. Despite its relevance to several symptom domains of SZ, this has received little attention in SZ research. In addition, while there is increasing evidence that SZ is associated with chronic low-grade inflammation, few studies have investigated how this relates to specific behaviors, such as balancing exploration and exploitation. We therefore assessed behaviors underlying the exploration-exploitation trade-off using a three-armed bandit task in 45 patients with SZ and 19 healthy controls (HC). This task allowed us to dissociate goal-unrelated (random) from goal-related (directed) exploration and correlate them with psychopathological symptoms. Moreover, we assessed a broad range of inflammatory proteins in the blood and related them to bandit task behavior. We found that, compared to HC, patients with SZ showed reduced task performance. This impairment was due to a shift from exploitation to random exploration, which was associated with symptoms of disorganization. Relative to HC, patients with SZ showed a pro-inflammatory blood profile. Furthermore, high-sensitivity C-reactive protein (hsCRP) positively correlated with random exploration, but not with directed exploration or exploitation. In conclusion, we show that low-grade inflammation in patients with SZ is associated with random exploration, which can be considered a behavioral marker for disorganization. hsCRP may constitute a marker for severity of, and a potential treatment target for maladaptive exploratory behaviors.

Entities:  

Year:  2021        PMID: 33536449     DOI: 10.1038/s41537-020-00133-0

Source DB:  PubMed          Journal:  NPJ Schizophr        ISSN: 2334-265X


  75 in total

Review 1.  Negative symptoms: the 'pathology' of motivation and goal-directed behaviour.

Authors:  R G Brown; G Pluck
Journal:  Trends Neurosci       Date:  2000-09       Impact factor: 13.837

2.  A tunable algorithm for collective decision-making.

Authors:  Stephen C Pratt; David J T Sumpter
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-12       Impact factor: 11.205

3.  Clarifying the overlap between motivation and negative symptom measures in schizophrenia research: A meta-analysis.

Authors:  Lauren Luther; Melanie W Fischer; Ruth L Firmin; Michelle P Salyers
Journal:  Schizophr Res       Date:  2018-12-19       Impact factor: 4.939

4.  Objective assessment of exploratory behaviour in schizophrenia using wireless motion capture.

Authors:  Ishraq Siddiqui; Gary Remington; Paul J Fletcher; Aristotle N Voineskos; Jason W Fong; Sarah Saperia; Gagan Fervaha; Susana Da Silva; Konstantine K Zakzanis; George Foussias
Journal:  Schizophr Res       Date:  2017-09-24       Impact factor: 4.939

Review 5.  A Primer on Foraging and the Explore/Exploit Trade-Off for Psychiatry Research.

Authors:  M A Addicott; J M Pearson; M M Sweitzer; D L Barack; M L Platt
Journal:  Neuropsychopharmacology       Date:  2017-05-29       Impact factor: 7.853

6.  Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses.

Authors:  P Rocca; S Galderisi; A Rossi; A Bertolino; P Rucci; D Gibertoni; C Montemagni; S Bellino; E Aguglia; M Amore; A Bellomo; M Biondi; B Carpiniello; A Cuomo; E D'Ambrosio; L dell'Osso; P Girardi; C Marchesi; P Monteleone; C Montemitro; L Oldani; F Pacitti; R Roncone; A Siracusano; E Tenconi; A Vita; P Zeppegno; L Steardo; A Vignapiano; M Maj
Journal:  Schizophr Res       Date:  2018-06-10       Impact factor: 4.939

7.  Rethinking schizophrenia.

Authors:  Thomas R Insel
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

8.  Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome.

Authors:  Gregory P Strauss; William P Horan; Brian Kirkpatrick; Bernard A Fischer; William R Keller; Pinar Miski; Robert W Buchanan; Michael F Green; William T Carpenter
Journal:  J Psychiatr Res       Date:  2013-02-27       Impact factor: 4.791

Review 9.  Schizophrenia.

Authors:  René S Kahn; Iris E Sommer; Robin M Murray; Andreas Meyer-Lindenberg; Daniel R Weinberger; Tyrone D Cannon; Michael O'Donovan; Christoph U Correll; John M Kane; Jim van Os; Thomas R Insel
Journal:  Nat Rev Dis Primers       Date:  2015-11-12       Impact factor: 52.329

10.  Neurocognitive abnormalities during comprehension of real-world goal-directed behaviors in schizophrenia.

Authors:  Tatiana Sitnikova; Donald Goff; Gina R Kuperberg
Journal:  J Abnorm Psychol       Date:  2009-05
View more
  7 in total

Review 1.  A review of risky decision-making in psychosis-spectrum disorders.

Authors:  John R Purcell; Emma N Herms; Jaime Morales; William P Hetrick; Krista M Wisner; Joshua W Brown
Journal:  Clin Psychol Rev       Date:  2021-12-20

2.  Piloting the Update: The Use of Therapeutic Relationship for Change - A Free Energy Account.

Authors:  Gernot Hauke; Christina Lohr
Journal:  Front Psychol       Date:  2022-04-11

3.  Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder.

Authors:  Flurin Cathomas; Karoline Guetter; Federica Klaus; Stefan Kaiser; Erich Seifritz
Journal:  Sci Rep       Date:  2021-05-11       Impact factor: 4.379

4.  Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia.

Authors:  Sara Costi; Laurel S Morris; Abigail Collins; Nicolas F Fernandez; Manishkumar Patel; Hui Xie; Seunghee Kim-Schulze; Emily R Stern; Katherine A Collins; Flurin Cathomas; Michael K Parides; Alexis E Whitton; Diego A Pizzagalli; Scott J Russo; James W Murrough
Journal:  Transl Psychiatry       Date:  2021-11-05       Impact factor: 7.989

5.  Associations Between Negative Symptoms and Effort Discounting in Patients With Schizophrenia and Major Depressive Disorder.

Authors:  Flurin Cathomas; Federica Klaus; Karoline Guetter; Erich Seifritz; Matthias N Hartmann-Riemer; Philippe N Tobler; Stefan Kaiser; Mariia Kaliuzhna
Journal:  Schizophr Bull Open       Date:  2021-06-11

Review 6.  The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines.

Authors:  Tomasz Boczek; Joanna Mackiewicz; Marta Sobolczyk; Julia Wawrzyniak; Malwina Lisek; Bozena Ferenc; Feng Guo; Ludmila Zylinska
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

7.  Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia.

Authors:  Flurin Cathomas; Stefan Kaiser; Federica Klaus; Karoline Guetter; Rebecca Schlegel; Tobias R Spiller; Erich Seifritz
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.